216 related articles for article (PubMed ID: 21910853)
1. Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.
Lenos K; de Lange J; Teunisse AF; Lodder K; Verlaan-de Vries M; Wiercinska E; van der Burg MJ; Szuhai K; Jochemsen AG
Mol Cancer; 2011 Sep; 10():111. PubMed ID: 21910853
[TBL] [Abstract][Full Text] [Related]
2. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of the p53 pathway in retinoblastoma.
Laurie NA; Donovan SL; Shih CS; Zhang J; Mills N; Fuller C; Teunisse A; Lam S; Ramos Y; Mohan A; Johnson D; Wilson M; Rodriguez-Galindo C; Quarto M; Francoz S; Mendrysa SM; Guy RK; Marine JC; Jochemsen AG; Dyer MA
Nature; 2006 Nov; 444(7115):61-6. PubMed ID: 17080083
[TBL] [Abstract][Full Text] [Related]
4. The alternative translated MDMX(p60) isoform regulates MDM2 activity.
Tournillon AS; López I; Malbert-Colas L; Naski N; Olivares-Illana V; Fåhraeus R
Cell Cycle; 2015; 14(3):449-58. PubMed ID: 25659040
[TBL] [Abstract][Full Text] [Related]
5. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.
Patton JT; Mayo LD; Singhi AD; Gudkov AV; Stark GR; Jackson MW
Cancer Res; 2006 Mar; 66(6):3169-76. PubMed ID: 16540668
[TBL] [Abstract][Full Text] [Related]
6. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
7. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
8. The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts.
Bandopadhayay P; Jabbour AM; Riffkin C; Salmanidis M; Gordon L; Popovski D; Rigby L; Ashley DM; Watkins DN; Thomas DM; Algar E; Ekert PG
BMC Cancer; 2013 Dec; 13():585. PubMed ID: 24321497
[TBL] [Abstract][Full Text] [Related]
9. Reduction of the tumorigenic potential of human retinoblastoma cell lines by TFF1 overexpression involves p53/caspase signaling and miR-18a regulation.
Busch M; Große-Kreul J; Wirtz JJ; Beier M; Stephan H; Royer-Pokora B; Metz K; Dünker N
Int J Cancer; 2017 Aug; 141(3):549-560. PubMed ID: 28481041
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
11. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
12. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics.
Vassilev LT
Cell Cycle; 2004 Apr; 3(4):419-21. PubMed ID: 15004525
[TBL] [Abstract][Full Text] [Related]
14. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.
Kan CE; Patton JT; Stark GR; Jackson MW
Cancer Res; 2007 Oct; 67(20):9862-8. PubMed ID: 17942917
[TBL] [Abstract][Full Text] [Related]
15. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation.
Boiko AD; Porteous S; Razorenova OV; Krivokrysenko VI; Williams BR; Gudkov AV
Genes Dev; 2006 Jan; 20(2):236-52. PubMed ID: 16418486
[TBL] [Abstract][Full Text] [Related]
16. MdmX promotes bipolar mitosis to suppress transformation and tumorigenesis in p53-deficient cells and mice.
Matijasevic Z; Steinman HA; Hoover K; Jones SN
Mol Cell Biol; 2008 Feb; 28(4):1265-73. PubMed ID: 18039860
[TBL] [Abstract][Full Text] [Related]
17. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
18. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent.
Lin J; Jin X; Page C; Sondak VK; Jiang G; Reynolds RK
Cancer Res; 2000 Oct; 60(20):5895-901. PubMed ID: 11059788
[TBL] [Abstract][Full Text] [Related]
19. Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest.
Lafontaine J; Rodier F; Ouellet V; Mes-Masson AM
PLoS One; 2012; 7(2):e31916. PubMed ID: 22355404
[TBL] [Abstract][Full Text] [Related]
20. Mdmx and Mdm2: brothers in arms?
Marine JC; Jochemsen AG
Cell Cycle; 2004 Jul; 3(7):900-4. PubMed ID: 15254433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
